Related Experiment Video

Updated: Jun 12, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

Novel inhibitors of mTORC1 and mTORC2

Shripad V Bhagwat1, Andrew P Crew

  • 1OSI Pharmaceuticals Inc, Department of Biochemical and Cellular Pharmacology, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA. sbhagwat@osip.com

Current Opinion in Investigational Drugs (London, England : 2000)
|May 25, 2010
PubMed

Insights

New ATP-competitive inhibitors target both mTORC1 and mTORC2, addressing limitations of rapamycin analogs. These novel agents show promise for cancer therapy by inhibiting the PI3K/Akt/mTOR pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is a key regulator of cell growth and survival, frequently hyperactivated in various human cancers.
  • Mammalian target of rapamycin (mTOR) is a validated therapeutic target, with mTOR complex 1 (mTORC1) inhibitors like rapamycin showing limited clinical efficacy.
  • The identification of rapamycin-insensitive mTOR complex 2 (mTORC2) in Akt activation necessitates the development of inhibitors targeting both complexes.

Purpose of the Study:

  • To review the development of selective ATP-competitive inhibitors targeting both mTORC1 and mTORC2.
  • To highlight novel inhibitors with improved efficacy over rapamycin analogs.
  • To focus on the clinical development profiles of these emerging mTOR inhibitors.

Main Methods:

  • Literature review of preclinical and clinical studies on mTOR inhibitors.
  • Analysis of the molecular mechanisms of ATP-competitive inhibitors targeting mTOR kinase.
  • Evaluation of clinical trial data for selective mTORC1/2 inhibitors.

Main Results:

  • ATP-competitive inhibitors effectively target both mTORC1 and mTORC2, overcoming rapamycin resistance.
  • Several novel selective mTORC1/2 inhibitors are in various stages of clinical development.
  • These inhibitors demonstrate potential for enhanced antitumor activity compared to mTORC1-specific agents.

Conclusions:

  • Selective ATP-competitive mTORC1/2 inhibitors represent a promising therapeutic strategy for cancers with activated PI3K/Akt/mTOR pathway.
  • Further clinical investigation is warranted to establish the efficacy and safety of these novel agents.
  • Targeting both mTORC1 and mTORC2 offers a more comprehensive approach to inhibiting this critical cancer pathway.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation09:37

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

Published on: March 15, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...